Equillium (EQ) Free Cash Flow (2018 - 2026)
Equillium (EQ) posted quarterly Free Cash Flow of -$4.3 million for Q1 2026, up 47.34% year-over-year from -$2.9 million in Q1 2025, and down 35.47% quarter-over-quarter from -$3.2 million in Q4 2025.
Powered by 
Analysis
Equillium (EQ) Free Cash Flow (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Free Cash Flow for 9 consecutive years, with -$4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 47.34% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at -$18.9 million (down 2.49% YoY), while the FY2025 annual figure was -$22.8 million, down 19.27% from the prior year.
- Free Cash Flow declined to -$4.3 million in Q1 2026 per EQ's latest filing, from -$3.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $27.4 million in Q4 2022 and bottomed at -$12.8 million in Q3 2022.
- Historically, Free Cash Flow has averaged -$4.5 million across 5 years, with a median of -$6.2 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 370.89% — and 2025, when it tumbled 551.05%.
- Equillium's Free Cash Flow stood at $27.4 million in 2022, then slumped by 120.76% to -$5.7 million in 2023, then soared by 42.04% to -$3.3 million in 2024, then rose by 3.81% to -$3.2 million in 2025, then slumped by 35.47% to -$4.3 million in 2026.
- Business Quant data shows EQ's Free Cash Flow at -$4.3 million in Q1 2026, -$3.2 million in Q4 2025, and -$8.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | -4.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.11 Mn |
| Mar 31, 2026 | -4.37 Mn |
| Dec 31, 2025 | -3.18 Mn |
| Sep 30, 2025 | -8.43 Mn |
| Jun 30, 2025 | -3.01 Mn |
| Mar 31, 2025 | -8.17 Mn |
| Dec 31, 2024 | -3.30 Mn |
| Sep 30, 2024 | -7.66 Mn |
| Jun 30, 2024 | 708,000.00 |
| Mar 31, 2024 | -8.86 Mn |
| Dec 31, 2023 | -5.70 Mn |
| Sep 30, 2023 | -1.91 Mn |
| Jun 30, 2023 | -6.22 Mn |
| Mar 31, 2023 | -8.00 Mn |
| Dec 31, 2022 | 27.72 Mn |
| Sep 30, 2022 | -13.07 Mn |
| Jun 30, 2022 | -11.31 Mn |
| Mar 31, 2022 | -12.36 Mn |
| Dec 31, 2021 | -10.13 Mn |
| Sep 30, 2021 | -7.04 Mn |